404 related articles for article (PubMed ID: 21156467)
1. Complete remission in two cases of adult T-cell leukemia/lymphoma treated with hyper-CVAD: a case report and review of the literature.
Alduaij A; Butera JN; Treaba D; Castillo J
Clin Lymphoma Myeloma Leuk; 2010 Dec; 10(6):480-3. PubMed ID: 21156467
[TBL] [Abstract][Full Text] [Related]
2. VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group Study JCOG9801.
Tsukasaki K; Utsunomiya A; Fukuda H; Shibata T; Fukushima T; Takatsuka Y; Ikeda S; Masuda M; Nagoshi H; Ueda R; Tamura K; Sano M; Momita S; Yamaguchi K; Kawano F; Hanada S; Tobinai K; Shimoyama M; Hotta T; Tomonaga M;
J Clin Oncol; 2007 Dec; 25(34):5458-64. PubMed ID: 17968021
[TBL] [Abstract][Full Text] [Related]
3. Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia.
Kantarjian H; Thomas D; O'Brien S; Cortes J; Giles F; Jeha S; Bueso-Ramos CE; Pierce S; Shan J; Koller C; Beran M; Keating M; Freireich EJ
Cancer; 2004 Dec; 101(12):2788-801. PubMed ID: 15481055
[TBL] [Abstract][Full Text] [Related]
4. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
5. Comparison of two different schedules of granulocyte-colony-stimulating factor during treatment for acute lymphocytic leukemia with a hyper-CVAD (cyclophosphamide, doxorubicin, vincristine, and dexamethasone) regimen.
Weiser MA; O'Brien S; Thomas DA; Pierce SA; Lam TP; Kantarjian HM
Cancer; 2002 Jan; 94(2):285-91. PubMed ID: 11900213
[TBL] [Abstract][Full Text] [Related]
6. Phase II study on combination therapy with CHOP-Zenapax for HTLV-I associated adult T-cell leukaemia/lymphoma (ATLL).
Ceesay MM; Matutes E; Taylor GP; Fields P; Cavenagh J; Simpson S; Ho A; Devereux S; Mufti GJ; Pagliuca A
Leuk Res; 2012 Jul; 36(7):857-61. PubMed ID: 22209076
[TBL] [Abstract][Full Text] [Related]
7. Relation between the duration of remission and hyperglycemia during induction chemotherapy for acute lymphocytic leukemia with a hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone/methotrexate-cytarabine regimen.
Weiser MA; Cabanillas ME; Konopleva M; Thomas DA; Pierce SA; Escalante CP; Kantarjian HM; O'Brien SM
Cancer; 2004 Mar; 100(6):1179-85. PubMed ID: 15022284
[TBL] [Abstract][Full Text] [Related]
8. R-hyper-CVAD versus R-CHOP/cytarabine with high-dose therapy and autologous haematopoietic stem cell support in fit patients with mantle cell lymphoma: 20 years of single-center experience.
Widmer F; Balabanov S; Soldini D; Samaras P; Gerber B; Manz MG; Goede JS
Ann Hematol; 2018 Feb; 97(2):277-287. PubMed ID: 29147847
[TBL] [Abstract][Full Text] [Related]
9. Multicenter analysis of treatment outcomes in adult patients with lymphoblastic lymphoma who received hyper-CVAD induction followed by hematopoietic stem cell transplantation.
Jeong SH; Moon JH; Kim JS; Yang DH; Park Y; Cho SG; Kwak JY; Eom HS; Won JH; Hong JS; Oh SY; Lee HS; Kim SJ
Ann Hematol; 2015 Apr; 94(4):617-25. PubMed ID: 25465233
[TBL] [Abstract][Full Text] [Related]
10. Adult T-Cell Leukemia/Lymphoma: Rarely Encountered in the United States.
Roe C; Komrokji R; Zhang L; Price S; Sokol L
Clin Lymphoma Myeloma Leuk; 2016 Aug; 16 Suppl():S191-4. PubMed ID: 27521318
[TBL] [Abstract][Full Text] [Related]
11. Complete remission in advanced blastic NK-cell lymphoma/leukemia in elderly patients using the hyper-CVAD regimen.
Shapiro M; Wasik MA; Junkins-Hopkins JM; Rook AH; Vittorio CC; Itakura H; Frankel MC; Georgala S; Schuster SJ
Am J Hematol; 2003 Sep; 74(1):46-51. PubMed ID: 12949889
[TBL] [Abstract][Full Text] [Related]
12. Four versus six courses of a dose-escalated cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) regimen plus etoposide (megaCHOEP) and autologous stem cell transplantation: early dose intensity is crucial in treating younger patients with poor prognosis aggressive lymphoma.
Schmitz N; Kloess M; Reiser M; Berdel WE; Metzner B; Dorken B; Kneba M; Trumper L; Loeffler M; Pfreundschuh M; Glass B;
Cancer; 2006 Jan; 106(1):136-45. PubMed ID: 16331635
[TBL] [Abstract][Full Text] [Related]
13. Clinical Features and Treatment Outcomes of 81 Patients with Aggressive Type Adult T-cell Leukemia-lymphoma at a Single Institution over a 7-year Period (2006-2012).
Kawano N; Yoshida S; Kuriyama T; Tahara Y; Yamashita K; Nagahiro Y; Kawano J; Koketsu H; Toyofuku A; Manabe T; Beppu K; Ono N; Himeji D; Yokota-Ikeda N; Inoue S; Ochiai H; Sonoda KH; Shimoda K; Ishikawa F; Ueda A
Intern Med; 2015; 54(12):1489-98. PubMed ID: 26073237
[TBL] [Abstract][Full Text] [Related]
14. Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia.
Thomas DA; Faderl S; O'Brien S; Bueso-Ramos C; Cortes J; Garcia-Manero G; Giles FJ; Verstovsek S; Wierda WG; Pierce SA; Shan J; Brandt M; Hagemeister FB; Keating MJ; Cabanillas F; Kantarjian H
Cancer; 2006 Apr; 106(7):1569-80. PubMed ID: 16502413
[TBL] [Abstract][Full Text] [Related]
15. Effects of first-line chemotherapy on natural killer cells in adult T-cell leukemia-lymphoma and peripheral T-cell lymphoma.
Ogura M; Ishida T; Tsukasaki K; Takahashi T; Utsunomiya A
Cancer Chemother Pharmacol; 2016 Jul; 78(1):199-207. PubMed ID: 27289375
[TBL] [Abstract][Full Text] [Related]
16. High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine.
Romaguera JE; Fayad L; Rodriguez MA; Broglio KR; Hagemeister FB; Pro B; McLaughlin P; Younes A; Samaniego F; Goy A; Sarris AH; Dang NH; Wang M; Beasley V; Medeiros LJ; Katz RL; Gagneja H; Samuels BI; Smith TL; Cabanillas FF
J Clin Oncol; 2005 Oct; 23(28):7013-23. PubMed ID: 16145068
[TBL] [Abstract][Full Text] [Related]
17. Effects of Mega-COMLA (cyclophosphamide, cytarabine, vincristine, and methotrexate followed by leucovorin and prednisone) plus CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) in the treatment of lymphoid neoplasms with very poor prognosis.
Hainsworth JD; Wolff SN; Stein RS; Greer JP; Cousar JB; Greco FA
Cancer Treat Rep; 1986 Aug; 70(8):953-8. PubMed ID: 3015406
[TBL] [Abstract][Full Text] [Related]
18. Hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone and highly active antiretroviral therapy for patients with acquired immunodeficiency syndrome-related Burkitt lymphoma/leukemia.
Cortes J; Thomas D; Rios A; Koller C; O'Brien S; Jeha S; Faderl S; Kantarjian H
Cancer; 2002 Mar; 94(5):1492-9. PubMed ID: 11920506
[TBL] [Abstract][Full Text] [Related]
19. High relapse rate of T cell acute lymphoblastic leukemia in adults treated with Hyper-CVAD chemotherapy in Sweden.
Kozlowski P; Åström M; Ahlberg L; Bernell P; Hulegårdh E; Hägglund H; Karlsson K; Markuszewska-Kuczymska A; Tomaszewska-Toporska B; Smedmyr B; Amini RM; Hallböök H;
Eur J Haematol; 2014; 92(5):377-81. PubMed ID: 24443846
[TBL] [Abstract][Full Text] [Related]
20. The hyper-CVAD-rituximab chemotherapy programme followed by high-dose busulfan, melphalan and autologous stem cell transplantation produces excellent event-free survival in patients with previously untreated mantle cell lymphoma.
Ritchie DS; Seymour JF; Grigg AP; Roberts AW; Hoyt R; Thompson S; Szer J; Prince HM
Ann Hematol; 2007 Feb; 86(2):101-5. PubMed ID: 17089127
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
